Filter posts

UN Proposals to Weaken IP Will Not Benefit Patients

Next week the 73rd session of the United Nations General Assembly (UNGA) will convene in …

The Role – and Value – of Public-Private Partnerships in Preparedness

Nearly twelve years ago, members of the biopharmaceutical supply chain, including BIO, came together in …

Medical Research from Mars Can Fail Patients from Venus

Historically, federal dollars inadvertently flowed to medical research with a disproportionate focus on men’s health. …

Bull Market Bodes Well for #BIF18

The rapid pace of scientific discovery, FDA approvals, commercialization of medicines held long in pipelines, …

Bloomberg Exposes How Drug Cost Middlemen “Rake in Millions”

Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit …

Greenwood Highlights Role of Innovation in Solving Opioid Crisis

The numbers are staggering. The opioid epidemic is costing our nation more than $500 billion annually in …

The Patient Perspective-Valuable for Drug Development

Congress, the Food and Drug Administration (FDA), drug developers, researchers and patient groups have all …

Hits to Patients Keep on Coming

At a time when prescription drug prices and spending are remarkably stable, patients are getting …

Healthcare AI is Booming

Emerging technologies are disrupting the healthcare system as we know it—none more so than artificial …

National Immunization Awareness Month is Timely Reminder of Modern Marvel of Vaccines

August marks National Immunization Awareness Month – a time to take inventory on where we …